Description
Recombinant Human TNFRSF8/CD30L Receptor/CD30 (C-mFc) | PKSH034046 | Gentaur US, UK & Europe Disrtribition
Synonyms: Tumor necrosis factor receptor superfamily member 8; CD30L receptor; Ki-1 antigen; Lymphocyte activation antigen CD30; CD30; TNFRSF8
Active Protein: N/A
Activity: Recombinant Human Tumor necrosis factor receptor superfamily member 8 is produced by our Mammalian expression system and the target gene encoding Phe19-Lys379 is expressed with a mFc tag at the C-terminus.
Protein Construction: Recombinant Human Tumor necrosis factor receptor superfamily member 8 is produced by our Mammalian expression system and the target gene encoding Phe19-Lys379 is expressed with a mFc tag at the C-terminus.
Fusion Tag: C-mFc
Species: Human
Expressed Host: Human Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 95 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per µg as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 64.8 kDa
Formulation: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.
Reconstitution: Please refer to the printed manual for detailed information.
Background: CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family, which regulates proliferation/apoptosis and antibody responses. CD30 is expressed by activated, but not by resting, T and B cells. Aberrant expression of CD30 by mastocytosis mast cells and interaction with its ligand CD30L (CD153) appears to play an important role in the pathogenesis and clinical presentation of systemic mastocytosis. CD30 has been considered as a specific diagnostic biomarker of anaplastic large cell lymphoma (ALCL) and classical Hodgkin lymphoma (cHL). CD30 is also a biomarker used for targeted therapy by an antibody–drug conjugate.
Research Area: Cancer, immunology
